抗药性金黄色葡萄球菌药物市场－全球产业规模、份额、趋势、机会及预测（依药物类别、给药途径、通路、地区及竞争格局划分，2021-2031年）

全球抗药性金黄色葡萄球菌(MRSA) 治疗市场预计将从 2025 年的 25.6 亿美元成长到 2031 年的 36.1 亿美元，复合年增长率达到 5.88%。

该市场主要由万古霉素和Linezolid等药物组成，这些药物是专门为对抗对β-内酰胺类抗生素抗药性的葡萄球菌感染疾病而配製的。推动这一增长的主要因素是医院获得性感染的日益增多，尤其是在老年人中，他们更容易出现慢性伤口，并且需要进行侵入性医疗操作。加护病房（ICU）中多重抗药性病原体的流行也进一步刺激了市场需求，因为那里迫切需要有效的治疗方法。除了广泛的抗菌药物管理措施外，这种情况还需要持续的药物解决方案。

然而，由于缺乏研发新型抗生素的经济奖励，市场面临严峻挑战，导致新药候选产品线有限。根据国际药品製造商协会联合会（IFPMA）2024年的数据，如果没有额外的投资，未来十年抗生素研发管线中仅有26种治疗方法能够问世，而目前只有6种处于后期研发阶段。后期临床治疗方案的匮乏凸显了製药公司在将新型耐甲氧西林金黄色葡萄球菌（MRSA）疗法商业化方面面临的巨大困难，尤其是在高昂的研发成本与低投资回报率之间存在巨大差距的情况下。

市场驱动因素

强大的临床研发管线和新型抗生素的核准是全球抗药性金黄色葡萄球菌(MRSA) 治疗市场的主要驱动力，显着改变了抗药性革兰氏阳性病菌感染的治疗模式。这项进展包括新一代头孢菌素类抗生素和其他新型药物的成功商业化，这些药物克服了万古霉素等标准疗法的限制。针对金黄色葡萄球菌菌血症 (SAB) 等高风险疾病的新型治疗方法的推出，也推动了市场的发展。例如，2025 年 5 月，巴塞尔製药宣布与 Innoviva Specialty Therapeutics 合作，在美国推出 Zebutera（头孢吡肟）。该合作计画包含高达 2.23 亿美元的销售里程碑，证明了治疗复杂 MRSA 适应症的商业性可行性。

同时，增加政府对抗生素研究的投入和奖励对于降低新型治疗方法研发风险和维持早期研发管线至关重要。鑑于低商业性回报抑制了私人投资，非营利伙伴关係和政府机构正在提供关键的「推动」资金，以帮助生物技术公司推进临床前候选药物的研发。例如，2025年1月，CARB-X向Immunartes公司津贴72.9万美元，用于加速开发一种能够中和金黄色葡萄球菌免疫逃脱机制的单株抗体。正如美国疾病管制与预防中心（CDC）在2024年11月指出的那样，这种资金支持对于应对感染率的波动至关重要。虽然上年度医院获得性抗甲氧西林金黄色葡萄球菌（MRSA）菌血症下降了16%，但仍需持续投资来应对特定病原体和社区获得性抗药性问题。

市场挑战

全球抗药性金黄色葡萄球菌（MRSA）治疗市场成长的主要障碍在于缺乏研发新型抗生素的经济奖励。与能够产生稳定收入的慢性病治疗药物不同，新型MRSA抗生素通常仅短期使用，且需遵守严格的药物管理计划，这些计划透过限制用药来维持疗效。这种结构性的市场失灵导致销售量与临床价值脱节，使得製药公司难以收回高昂的研发成本或获得足够的投资回报。因此，产业巨头纷纷退出该领域，将重担转移到小规模的生技公司身上，而这些公司往往缺乏足够的财力来应对昂贵的监管核准流程。

这种财务不稳定直接限制了治疗抗药性菌株所需的创新治疗方法的商业性化应用。据抗菌药物抗药性产业联盟（AMR Industry Alliance）称，其成员公司预计到2024年每年将在抗生素研发方面投入约20亿美元，但业内人士认为这笔金额不足以维持强大的新药研发管线。这种投资不足限制了新型耐甲氧西林金黄色葡萄球菌（MRSA）疗法的推出，进而限制了整个市场的获利能力。

市场趋势

全球抗药性金黄色葡萄球菌(MRSA) 治疗市场正因新型非抗生素疗法的出现而重塑，这些疗法利用精准工具绕过传统的抗药性机制。与常会破坏宿主微生物群的频谱抗生素不同，噬菌体和溶素等先进治疗方法特异性靶向细菌毒力因子，从而根除多重抗药性菌株。在该领域，Faqiam Therapeutics 公司于 2024 年 11 月获得 FDA核准，进行一项评估其专有特异性噬菌体疗法的 II 期临床试验，这是一项重大进展。这种向高特异性生物製药的转变，为那些对标准药物疗法无效的复杂生物膜相关感染疾病患者提供了至关重要的替代方案。

同时，人工智慧（AI）正日益融入抗生素药物研发领域，加速从庞大的化合物库中筛选出有前景的候选药物，从而解决该领域普遍存在的高失败率和高成本问题。深度学习演算法使研究人员能够快速预测分子对金黄色葡萄球菌的疗效和毒性，并从以往难以获得的微生物资源中发现新的化学骨架。作为对这项技术投资的一个象征性例证，亥姆霍兹感染疾病研究中心于2024年11月宣布，已向一个欧洲联盟授予1100万欧元的津贴，用于开发一个针对包括耐甲氧西林金黄色葡萄球菌（MRSA）在内的重点病原体的抗生素研发人工智慧平台。这体现了数据驱动方法对于重振药物研发生态系统至关重要。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球抗药性金黄色葡萄球菌药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 药物类别（Oxazolidinone、脂肽类、头孢菌素类、四环霉素、叶酸拮抗剂类、其他）
  • 依给药途径（口服、注射给药）
  • 按分销管道（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美抗药性金黄色葡萄球菌药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲抗药性金黄色葡萄球菌药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区抗药性金黄色葡萄球菌药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲抗药性金黄色葡萄球菌药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲抗药性金黄色葡萄球菌药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球抗药性金黄色葡萄球菌药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Melinta Therapeutics LLC
• Basilea Pharmaceutica Ltd.
• Theravance Biopharma
• Wockhardt Limited
• Paratek Pharmaceuticals, Inc.
• Seres Therapeutics Inc.
• Merck & Co. Inc.
• AbbVie Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Methicillin-resistant Staphylococcus Aureus Drugs Market is projected to expand from USD 2.56 Billion in 2025 to USD 3.61 Billion by 2031, achieving a CAGR of 5.88%. This market largely consists of pharmaceutical agents, including vancomycin and linezolid, which are specifically formulated to combat staphylococcal infections resistant to beta-lactam antibiotics. A key driver of this growth is the increasing prevalence of hospital-acquired infections, particularly among the aging population, who are more prone to chronic wounds and require invasive medical procedures. Furthermore, the demand is intensified by the urgent need for effective therapies in intensive care units, where multidrug-resistant pathogens persist, requiring continuous pharmaceutical solutions separate from broader antibiotic stewardship efforts.

However, the market faces a substantial challenge due to the lack of economic incentives for developing new antimicrobials, resulting in a restricted pipeline of novel candidates. Data from the International Federation of Pharmaceutical Manufacturers and Associations in 2024 indicates that, without additional investment, the antibiotic pipeline will yield only 26 treatments over the next decade, with merely six currently in late-stage development. This scarcity of late-stage clinical options highlights the significant difficulties pharmaceutical companies encounter in commercializing new MRSA drugs, particularly given the disparity between high research costs and low returns on investment.

Market Driver

The robust clinical pipeline and the approval of novel antibiotic classes serve as major catalysts for the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, significantly altering the treatment landscape for resistant gram-positive infections. This progress involves the successful commercialization of advanced-generation cephalosporins and other novel agents that address the limitations of standard therapies like vancomycin. Significant momentum is evident with the introduction of new therapies for high-risk conditions such as Staphylococcus aureus bacteremia (SAB). For example, Basilea Pharmaceutica announced in May 2025 the US launch of Zevtera (ceftobiprole medocaril), a partnership with Innoviva Specialty Therapeutics that includes potential sales milestones reaching USD 223 million, validating the commercial viability of treating complex MRSA indications.

Concurrently, increased government funding and incentives for antimicrobial research are essential for sustaining the early-stage pipeline by de-risking the development of new treatments. Recognizing the market failure where low commercial returns deter private investment, non-profit partnerships and government bodies provide crucial "push" funding to help biotech firms advance preclinical candidates. For instance, CARB-X awarded US$729,000 to Immunartes in January 2025 to accelerate a monoclonal antibody designed to neutralize S. aureus immune-evasion mechanisms. This financial support is vital to counter fluctuating infection rates, as noted by the CDC in November 2024; although hospital-onset MRSA bacteremia decreased by 16% the prior year, continued investment is necessary to address niche and community-associated resistance.

Market Challenge

A primary barrier inhibiting the growth of the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is the lack of economic incentives for developing new antimicrobials. Unlike medications for chronic diseases that provide steady revenue, novel MRSA antibiotics are usually prescribed for short durations and are subject to strict stewardship programs that limit their use to preserve efficacy. This structural market failure disconnects sales volume from clinical value, making it extremely difficult for pharmaceutical companies to recover high research and development costs or achieve a viable return on investment. Consequently, major industry players have exited the sector, shifting the burden to smaller biotechnology firms that often lack the capital to navigate the expensive regulatory approval process.

This financial instability directly restricts the commercial availability of innovative therapies needed to treat resistant strains. According to the AMR Industry Alliance, member companies reported a collective annual investment of approximately USD 2 billion in antimicrobial research and development in 2024, a figure the industry describes as insufficient to maintain a robust pipeline of new medicines. This stagnation in investment limits the introduction of new MRSA drugs, thereby constraining the overall revenue potential of the market.

Market Trends

The Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is being reshaped by the emergence of novel non-antibiotic therapeutic modalities that utilize precision tools to bypass traditional resistance mechanisms. Unlike broad-spectrum antibiotics that often disrupt the host microbiome, advanced options such as bacteriophages and lysins specifically target bacterial virulence factors to eradicate multidrug-resistant strains. A significant development in this area occurred in November 2024, when Phaxiam Therapeutics received FDA approval to launch a Phase II clinical trial evaluating its specialized phage therapy. This shift toward high-specificity biologics offers a critical alternative for patients with complex, biofilm-associated infections that do not respond to standard pharmacotherapy.

Simultaneously, the integration of Artificial Intelligence into antimicrobial drug discovery is accelerating the identification of potent candidates from vast chemical libraries, addressing the high attrition rates and costs typical of the sector. Deep learning algorithms enable researchers to rapidly predict molecular efficacy and toxicity against Staphylococcus aureus, uncovering novel chemical scaffolds from previously inaccessible microbial sources. Highlighting the investment in this technology, the Helmholtz Centre for Infection Research reported in November 2024 that a European consortium received a EUR 11 million grant to develop an AI-based platform for discovering antibiotics for priority pathogens, including MRSA, representing a data-driven approach vital for revitalizing the discovery ecosystem.

Key Market Players

• Melinta Therapeutics LLC
• Basilea Pharmaceutica Ltd.
• Theravance Biopharma
• Wockhardt Limited
• Paratek Pharmaceuticals, Inc.
• Seres Therapeutics Inc.
• Merck & Co. Inc.
• AbbVie Inc.

Report Scope

In this report, the Global Methicillin-resistant Staphylococcus Aureus Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Methicillin-resistant Staphylococcus Aureus Drugs Market, By Drug Class

• Oxazolidinones
• Lipopeptides
• Cephalosporin
• Tetracycline
• Folate Antagonist
• Other

Methicillin-resistant Staphylococcus Aureus Drugs Market, By Route of Administration

• Oral Administration
• Parenteral Administration

Methicillin-resistant Staphylococcus Aureus Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Methicillin-resistant Staphylococcus Aureus Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Methicillin-resistant Staphylococcus Aureus Drugs Market.

Available Customizations:

Global Methicillin-resistant Staphylococcus Aureus Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, Folate Antagonist, Other)
  • 5.2.2. By Route of Administration (Oral Administration, Parenteral Administration)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Methicillin-resistant Staphylococcus Aureus Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Melinta Therapeutics LLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Basilea Pharmaceutica Ltd.
• 15.3. Theravance Biopharma
• 15.4. Wockhardt Limited
• 15.5. Paratek Pharmaceuticals, Inc.
• 15.6. Seres Therapeutics Inc.
• 15.7. Merck & Co. Inc.
• 15.8. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer